TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
AlgEternal Ups Production With OriginClear Technology
Clinicians in the not-too-distant future may have something new to offer women with breast cancer and ovarian cancer in whom initial therapy fails to yield a response.
TapImmune will be hosting an investor breakfast at the Blackstone hotel tomorrow, May 17th from 7:30am-10am. Come and meet with with Marker Co-Founders Juan Vera, M.D. and Ann Leen, Ph.D., and former President of the American Society for Gene and Cell Therapy Malcolm Brenner along with TapImmune Management. Read: TapImmune, Marker Merger to Significantly Disrupt…Details
TapImmune has snapped up privately-owned Marker Therapeutics to create a new company based on a non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune is planning to raise money to support its expanded pipeline.
TapImmune expanded its immuno-oncology capabilities today with a deal to acquire Marker Therapeutics and its clinical-stage, multi-antigen T cell therapy platform.
TapImmune, the Jacksonville-based developer of cancer fighting immunotherapies, is merging with Marker Therapeutics Inc., a Minnesota-based developer of similar T-cell therapies.
WaterChain Cryptocoin to Fund Decentralized Water Projects
WaterChain seeks to accelerate development of water projects as the world faces a looming shortage. It’s a staggering statistic. 6000 children die each day from the effects of unclean drinking water. In the time it took you to read that sentence, a child died, lacking something most of us take for granted. WaterChain is a new…Details
Water is Life, and OriginClear’s WaterChain is Putting it on the Blockchain